United States Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy), By Scale (Pre-Commercial/R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-House Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Vector Production, Others), By Process (Upstream Processes, Downstream Processes), By End-User (Pharmaceutical Companies, Biopharmaceutical/Biotechnological Companies, Contract Manufacturing Organizations), By Technology Type (FACS, ELISA, Chromatography, PCR, Others), Forecasts, 2026-2034

United States Cell and Gene Therapy Manufacturing QC Market Size

The Asia Pacific Automotive Parts Aluminum Die Casting Market size was valued at USD 9.46 billion in 2025 and is projected to grow from USD 10.28 billion in 2026 to USD 20.04 billion by 2034 at a CAGR of 8.7% during the forecast period 2026–2034.

This market is experiencing rapid growth, driven by the surging efforts of key players to technologically advance these QC solutions. In addition, there has also been a rise in government and public initiatives supporting research and development in this field, thereby creating opportunities for market growth.

Process Insights

Upstream Processes dominates the process segment and is estimated to grow at a CAGR of 25.3%. The upstream processes segment in the U.S. cell and gene therapy manufacturing QC market is witnessing significant growth due to increasing demand for robust cell expansion and viral vector production. These processes are crucial for scaling up therapeutic manufacturing and ensuring high-quality yields for both clinical and commercial applications.

Request Customizationto receive a tailored report.

End User Insights

Biopharmaceutical/biotechnological companies are estimated to own the end-user segment and are anticipated to expand at a CAGR of 25.2%. Biopharmaceutical and biotechnological companies are driving the market's growth due to their heavy investments in cell and gene therapy development. These companies focus on in-house QC processes to meet regulatory requirements, ensuring the safe production of advanced therapies and accelerating commercialization in this growing therapeutic field.

Technology Type Insights

Polymerase Chain Reaction (PCR) dominates the technology type segment and is expected to augment at a CAGR of 26.0%. The Polymerase Chain Reaction (PCR) technology segment is expanding due to its precision and effectiveness in detecting genetic modifications and viral vectors in these therapies. PCR's high sensitivity and rapid results make it an essential QC tool, particularly in ensuring the safety and efficacy of cell and gene-based products.

Speak to an Analystto discuss market opportunities.

Country Insights

The U.S. is a global leader in cell and gene therapy research and development, making it the largest market. The Northeast U.S. is home to major biotech hubs, particularly in Massachusetts (Boston-Cambridge area) and New Jersey, which are pivotal in the cell and gene therapy space. According to the Massachusetts Biotechnology Council, Massachusetts alone has more than 1,000 biopharmaceutical companies involved in advanced therapies, accounting for 20% of the global pipeline for gene therapies.

Additionally, California is another key region, with numerous firms focused on gene therapy development. The San Francisco Bay Area and San Diego are major biotech hubs in California, with companies like Sangamo Therapeutics and Audentes Therapeutics leading gene therapy development. California's gene therapy sector has seen a 33% increase in investment between 2018 and 2022, driven by VC funding and collaborations with academic institutions. The state's focus on innovation and R&D is positioning California as a leading region for QC technology adoption.

Furthermore, while traditionally known for pharmaceutical manufacturing, regions like Texas (Houston) and North Carolina (Research Triangle Park) are emerging as key players in the market. North Carolina's Research Triangle Park has attracted 20+ gene therapy companies, including AveXis and Precision BioSciences, due to the state's competitive operating costs and workforce availability.

Texas, particularly Houston, is becoming a prominent region due to institutions like MD Anderson Cancer Center, which has collaborated on CAR-T therapies and is driving clinical trial growth in cell therapy. This expansion is expected to increase the demand for local QC testing facilities to ensure compliance with federal and state regulations.

List of Key and Emerging Players in United States Cell and Gene Therapy Manufacturing QC Market